Lorde Announces 2018 North American Tour Following Release Of "Melodrama"

It’s hard to believe that both “Royals” and Lorde’s debut album “Pure Heroine” are already 4 years old, with the New Zealand-born songstress being just 16 years old at the time. Since then, she’s enjoyed massive critical and financial success with 3 other charting singles en route to “Pure Heroine” being certified 3x Platinum. Additionally she’s curated the soundtrack for The Hunger Games, performed alongside the surviving members of Nirvana and headlined many festivals worldwide. But until now, the arrival of her sophomore album or world tour were a mystery.

That all changed in June 2017 when Lorde released “Melodrama” to the public along with announcing her 2017/2018 World Tour. Set to kick off this September in the UK, Lorde’s tour also includes 30 (thus far) North American venues beginning in March.

With Pre-Sale already underway for the North American dates and the proper on-sale this Friday June 23rd, a number of Lorde World Tour tickets have already hit the secondary market. On average, there’s already over 8,000 tickets available for the arena tour.

Looking at the secondary market, Connecticut’s Mohegan Sun Arena on April 7th is currently the tour’s most expensive North American date, with an average asking price of $432. Conversely, March 27 at Chicago’s Allstate Arena is the cheapest of the trek, marking just an $157 average ticket price. April 3rd at Boston’s TD Garden and April 4th at Brooklyn’s Barclays Center currently have the largest markets, with over 600 tickets on the resale market for each. The cheapest ticket available (“Get-in” price) for most dates hovers around $55. Either way, it’s a stark contrast from her 2013-2014 tour which saw her play primarily smaller venues and amphitheaters.

With the long awaited return to touring and a sophomore effort sporting an even more mature sound to what already was an artist well beyond her years, Lorde looks to be one of the hottest tour tickets in 2018.

[embedit cf="HTML1"]

Related Articles